Perampanel, a first-in-class substance (a non-competitive AMPA receptor antagonist), is used to treat patients with epilepsy aged 12 and older. Specifically, it is used as adjunctive therapy for partial onset seizures (with or without secondarily generalized seizures) and primary generalized tonic-clonic (PGTC) seizures.
Perampanel is administered orally once a day. It is a Schedule III controlled drug substance. Epilepsy is a brain disorder in which abnormal or excessive electrical activity of nerve cells causes symptoms such as sudden movements or major convulsions.
Partial seizures, the most common form, affect only a limited or localized area of the brain, but can spread to other parts of the brain (causing secondarily generalized seizures). Generalized tonic-clonic seizures affect the whole brain.
Perampanel was approved for use by the FDA and EMA in 2012, under the trade name Fycompa. It is produced through multi-step chemical synthesis.